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| INTRODUC TI ON
Crohn's disease (CD) is a chronic, relapsing, progressive disease characterized by immune-mediated inflammation in the gastrointestinal tract. 1 The incidence and prevalence of CD is increasing worldwidely. 1, 2 In the absence of aetiological treatment, medical therapy with the purpose of inducing and maintaining remission plays a key role in the management of CD. 3 Safer and more effective drugs need to be found to compensate for the shortcomings of current medical treatments. 1, 3 Although the pathogenesis of CD remains largely unknown, CD is considered a disease arising from an interaction between genetic and environmental factors. 1 Over activated T helper cell type 1 (Th1) and T helper cell type 17 (Th17) immune responses contribute to intestinal damage in CD. 4 Regulatory T cells (Tregs), which are required for controlling excessive inflammation and maintaining immune homeostasis, also play an essential role in the pathogenesis of CD.
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Undoubtedly, intestinal mucosal inflammation can indirectly or directly damage the intestinal barrier. 6 The intestinal epithelium at the interface between the intestinal microbiome/other antigens and the lymphoid tissue associated with the gastrointestinal system plays a critical role in shaping the mucosal immune response. 7, 8 In addition, the inflammatory response often results in continued epithelial injury, which causes erosions and ulcerations. Indirect data suggest that a barrier defect might precede the onset of disease. 7 This conclusion stems from the fact that even patients with quiescent CD exhibit increased paracellular permeability. 9 However, there is no answer to the question of whether barrier dysfunction is a cause or consequence of CD. It seems that cross-talk between the impaired intestinal barrier and abnormal intestinal mucosal immune responses plays an important role in the occurrence and development of CD.
The diseased bowel could be removed by surgery, however, recurrence would still occur after surgery. In fact, CD is a disease with a tendency to relapse for life. However, protecting the intestinal mucosal barrier or regulating intestinal mucosal immunity should be beneficial to CD patients. 10 Interleukin (IL)-10 gene-deficient (Il-10 −/− ) mice are recognized as a CD animal model with intestinal barrier defects and abnormal intestinal mucosal immunity similar to those in human CD. 11, 12 We have long been committed to the study of how to improve the intestinal barrier and intestinal mucosal immunity in Il-10 −/− mice from multiple perspectives, including inhibiting Th1/Th17 immune responses, 13 promoting Treg activities, 14, 15 limiting intestinal mucosal epithelial cell apoptosis, 14, 16 protecting intestinal epithelial tight junction (TJ) proteins 17 and regulating autophagy. 15 However, we still think more agents, particularly drugs with the potential for rapid clinical application, should be developed to meet CD treatment needs.
Bryostatin-1 (Bry-1) is a naturally occurring macrocyclic lactone obtained from the marine bryozoan Bugula neritina. 18 Previous stud- In the present study, we investigated the effects of Bry-1 on spontaneous CD-like colitis in Il-10 −/− mice and the possible mechanism of these effects with the hope of providing a new therapeutic option for CD.
| MATERIAL S AND ME THODS

| Mice
Our experimental procedures were approved by the Animal Ethics 
| Drug administration protocol
Fifteen-week-old male Il-10 −/− mice with spontaneous enteritis were divided into positive control (IL-10 −/− ) and Bry-1-treated groups (Bry-1). Age-matched male WT mice were used as negative controls (WT). Each group in this study contained eight mice.
Bry-1 with a purity ≥99% (solid) was purchased from Sigma-Aldrich and 1% DMSO in PBS) every other day for 4 weeks, as previously described. 20 After 4 weeks, the mice were killed under anaesthesia.
The entire colon was collected, carefully rinsed with PBS and prepared for subsequent examination.
| Colitis symptom assessment
Each Il-10 −/− mouse was scored weekly with the inflammatory bowel disease activity index (DAI) using the numerical system described by Spencer et al 23 Briefly, the DAI was calculated by scoring 1 point for the appearance of each of the following characteristics: ruffled fur, occult faecal blood, rectal prolapse <1 mm and soft stool, with an additional point for diarrhoea or severe rectal prolapse >1 mm. The DAI was calculated on a 6-point (0-5) scale.
| Histological analysis
Tissue from the colon was routinely stained with haematoxylin and eosin (H&E) and analysed for morphological changes. The intestinal inflammation grading was performed as previously described. 
| Intestinal permeability in vivo
As we previously described, 25 the mice were fasted for 4 hours and then administered fluorescein isothiocyanate (FITC)-dextran (4 kDa; Sigma-Aldrich, Cat#: FD4, St. Louis, MO) by gavage at a dose of 600 mg/kg. After 4 hours, the mice were killed and bled by cardiac puncture. The serum was isolated using centrifugation, and the serum FITC levels were evaluated using fluorometry.
| Bacterial translocation
As we previously described, 25 
| Western blot analysis
Whole-cell and nuclear protein extracts were prepared from tissue homogenates as previously described, 27 and Western blot analysis was conducted as previously described. 28 Briefly, the protein extracts from the tissue homogenate were separated by SDS-PAGE and transferred to PVDF membranes for immunoblotting.
The primary antibodies used were 1:1 000 dilutions of rabbit polyclonal antibodies against Claudin-1, Occludin, Bcl-2, Bax, cleaved Caspase-3, nuclear factor erythroid 2-related factor 2 (Nrf2; 
| Flow cytometry
T cell responses were analysed by flow cytometry as previously and the data were analysed using FlowJo V10 software.
| Enzyme-linked immunosorbent assay (ELISA)
IL-17A (R&D Systems, Cat#: PM1700, Emeryville, CA), IFN-γ (R&D Systems Cat#: PMIF00) and TNF-α (R&D Systems, Cat#: PMTA00B) expression levels in the intestine were determined by ELISAs. Briefly, intestinal tissue was homogenized in 1 mL of normal saline. Then, the homogenates were centrifuged at 3000 rpm at 4°C for 30 minutes, and the supernatant was stored at −80°C until analysis.
| Quantitative real-time PCR (qRT-PCR) analysis
The Ifn-γ, Tnf-α, Il-17A, Nrf2 and HO-1 mRNA levels were measured using qRT-PCR analysis as previously described. 
| Immunofluorescence
Immunofluorescence was assessed as described previously. 
| Immunohistochemical analysis
The intestinal levels of p-STAT3 and p-STAT4 were determined by immunohistochemical analysis as previously described. 
| Statistical analysis
The data analyses were performed using Statistical Package for Social Sciences (SPSS; SPSS Inc, Chicago, IL) version 23.0.
Continuous, normally distributed data are presented as the mean ± standard deviation (SD). Unpaired t tests were used to compare data between two groups. The binary and categorical data were compared using chi-squared tests to produce the contingency tables. Fisher's exact test was performed when the sample number was ≤5. All tests were two-sided. A P value <0.05 was considered statistically significant.
Gene name Forward primer Reverse primer
Ifn-γ ACAGCAAGGCGAAAAAGGATG TGGTGGACCACTCGGATGA
Tnf-α CAGGCGGTGCCTATGTCTC CGATCACCCCGAAGTTCAGTAG
Il-17A TCTCAGGCTCCCTCTTCAG GACTCTCCACCGCAATGA TNF-α, tumour necrosis factor-α; and NS, no significance. At least three independent experiments with six to eight mice in each group were performed, with one representative experiment is shown. The data are expressed as the mean ± SD. ▼ P < 0.05 the submicroscopic level ( Figure 2E ). We found that the ultrastructural morphology of the TJs in intestinal villi was damaged in the untreated Il-10 −/− mice, and this damage was characterized by decreased amounts of electron-dense materials in the TJs ( Figure 2E , white arrows) and abnormal desmosomes ( Figure 2E , white arrowheads).
Nrf2
CGAGATATACGCAGGAGAGGTAAGA GCTCGACAATGTTCTCCAGCTT
HO-1 CTCCCTGTGTTTCCTTTCTCTC GCTGCTGGTTTCAAAGTTCAG
Gapdh
However, the damaged TJ structure was improved in the Bry-1-treated Il-10 −/− mice. These results indicated that treatment with Bry-1 could ameliorate the damage to the intestinal barrier structure. The ultrastructural morphology of the TJ structures of intestinal villi was damaged in Il-10 −/− mice, and the damaged was characterized by decreased amounts of electron-dense materials in the TJs (E, white arrows) and abnormal desmosomes (E, white arrowheads). These damaged TJ structures were improved in Bry-1-treated Il-10 −/− mice. Bry-1, Bryostatin-1; WT, wild-type; TJ, tight junction; and NS, no significance. At least three independent experiments with six to eight mice in each group were performed, with one representative experiment is shown. The data are expressed as the mean ± SD. ▼ P < 0.05 untreated Il-10 −/− mice in both the spleen (E and F) and MLN (G and H), but these T lymphocyte proportions were still higher than those in WT mice. Bry-1, Bryostatin-1; WT, wild-type; MLN, mesenteric lymph nodes; and NS, no significance. At least three independent experiments with six to eight mice in each group were performed, with one representative experiment is shown. The data are expressed as the mean ± SD. ▼ P < 0.05 in the WT mice ( Figure 4C,D) . In contrast, compared to the untreated Il-10 −/− mice, the Bry-1-treated Il-10 −/− mice showed significant decreases in the Bax and cleaved caspase-3 levels, but the levels in the Bry-1-treated mice were still higher than those in the WT mice ( Figure 4C,D) . These results indicated that the protective effect of Bry-1 on Il-10 −/− mice was at least partly mediated through preventing intestinal epithelial cell apoptosis.
3.5 | Antiapoptotic effect of Bry-1 on Il-10 −/− mice may be partly mediated by activating Nrf2 signalling
We are interested in the antiapoptotic mechanism of Bry-1, and recently published research showing that the Nrf2 signal is an important antiapoptotic signal. [34] [35] [36] As shown in Figure 5 , the levels of both Nrf2 and its downstream factor HO-1 were significantly increased in the Bry-1-treated Il-10 −/− mice compared to the untreated Il-10 −/− mice, and the levels in Bry-1-treated Il-10 −/− mice were similar to those in the WT mice ( Figure 5A ,B). These results were confirmed by PCR ( Figure 5C ). These data indicated that Nrf2 signalling activation may be one of the antiapoptotic mechanisms of Bry-1. Using TEM, we found more direct evidence that Bry-1 protected the TJ structures of intestinal mucosal epithelial cells in Il-10 −/− mice.
| Bry-1 treated
Increased intestinal permeability is an important factor in causing or maintaining intestinal inflammation in CD. 6 Our results indicated that In addition, the inhibition of STAT3 contributes to the activation of
Tregs. 41 These findings may partly explain the effects of Bry-1 on the intestinal mucosal immune response in CD-like colitis.
The findings of our study have potential clinical implications.
Given the rising incidence of CD and the importance of drug therapy, research teams, including our team, are looking for possible new drugs. However, drugs that have the potential to be applied in the clinic soon may be more valuable than those that will still require extensive research. In fact, to the best of our knowledge, Bry-1 has been studied for more than 30 years. 42 Previous studies have shown that Bry-1 has immunomodulatory, anti-oxidant and anti-inflammatory effects, suggesting its potential clinical application value.
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Although the biological functions of Bry-1 have not been fully revealed, in the past 10 years, more than 20 clinical trials have been conducted with Bry-1 as a monotherapy or in combination with clinically used cytotoxic drugs. 43 A recent clinical trial confirmed the efficacy and safety of Bry-1 in the treatment of Alzheimer's disease.
21
Even more exciting findings in recent research have shown that
Bry-1 has therapeutic potential in progressive forms of multiple sclerosis, which have immune response types similar to those of CD.
20
We hope that Bry-1 may benefit CD patients in the future.
Our study has some limitations. For example, our results showed that Bry-1 protects against CD-like colitis by improving the intestinal barrier and the abnormal intestinal mucosal immune response;
however, Bry-1 could also improve colitis through other means.
The changes in Nrf2 and STAT3/4 signalling may partly explain the mechanism underlying the treatment effects of Bry-1, but we may have ignored other signalling pathways. It seems likely that Bry-1 has multiple biological functions, as previously reported.
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In conclusion, this study provides initial evidence that the systemic delivery of Bry-1 ameliorates spontaneous colitis in Il-10 −/− mice, and this effect is associated with the attenuation of intestinal barrier injury and the abnormal intestinal mucosal immune response.
The protective effect of Bry-1 on CD-like colitis, particularly given the established clinical safety of Bry-1, suggests Bry-1 will have therapeutic potential in human CD.
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